You are here
Cryoablation versus Partial Nephrectomy for Clinical T1b Renal Tumors: A Matched Group Comparative Analysis
Editorial comment from Piotr Chlosta: Patients treated with cryoablation(CA) for cT1b renal tumors had a significantly higher rate of local cancer recurrence at 1 year compared to those treated with partial nephrectomy (PN). The authors found a higher but not significantly different postoperative complication rate for the PN group, a significantly higher local recurrence rate for the CA group, and similar overall and cancer-specific survival. The role of CA for cT1b RCC need to be determined.
Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial
Haas NB, Manola J, Dutcher JP, Flaherty KT, Uzzo RG, Atkins MB, et al.
Editorial comment from Piotr Chlosta: Analysis of data from ASSURE trial showed that adjuvant treatment with sunitinib or sorafenib did not improve disease-free survival in high-risk subset of patients with clear cell RCC.
Impact of antibiotics on outcome in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors
L. Derosa, B. Routy, D. Enot, G. Baciarello, C. Massard, Y. Loriot, et al.
Editorial comment from Prof. Piotr Chlosta:
This retrospective analysis suggests efficacy of immunotherapy may be lower in patients receiving antibiotic less than a month before starting treatment. Relationship between the gut microbiome and response to immunotherapy should be further investigated.
European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor–Targeted Therapy
Editorial comment from Piotr Chlosta:
Following publication of data from pivotal trials, the European Association of Urology renal cancer guidelines panel recommends nivolumab and cabozantinib over the previous standard of care in patients who have failed one or more lines of VEGF-targeted therapy.
Outcomes Following Complete Surgical Metastasectomy for Patients with Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
Zaid HB, Parker WP, Safdar NS, Gershman B, Erwin PJ, Murad MH, et al.
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC)
BJU Int. 2014 Oct;114(Suppl 4):2
Clinical and radiographic predictors of the need for resection of the inferior vena cava during nephrectomy for patients with renal cell carcinoma and caval tumor thrombus
BJU Int. 2014 Oct;114(Suppl 4):14-15.
SWITCH trial: Similar progression-free and overall survival outcomes regardless of sorafenib-sunitinib sequence in mRCC
Commentary from Professor Susanne Osanto